BIOCRYST PHARMACEUTICALS INC (BCRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 350M 700M 1.1B Q4 '10: 62.4M Q1 '11: 41.7M Q2 '11: 37.9M Q3 '11: 31.1M Q4 '11: 19.6M Q1 '12: 26.4M Q2 '12: 26.9M Q3 '12: 27.4M Q4 '12: 26.3M Q1 '13: 17.6M Q2 '13: 14.2M Q3 '13: 10.9M Q4 '13: 17.3M Q1 '14: 17.2M Q2 '14: 17.9M Q3 '14: 18.7M Q4 '14: 13.6M Q1 '15: 17M Q2 '15: 41.4M Q3 '15: 49.1M Q4 '15: 48.3M Q1 '16: 46.3M Q2 '16: 25.2M Q3 '16: 22M Q4 '16: 26.4M Q1 '17: 31M Q2 '17: 29.3M Q3 '17: 30.3M Q4 '17: 25.2M Q1 '18: 19.7M Q2 '18: 29.1M Q3 '18: 21.8M Q4 '18: 20.7M Q1 '19: 22.6M Q2 '19: 11.5M Q3 '19: 11.8M Q4 '19: 48.8M Q1 '20: 47.8M Q2 '20: 49.2M Q3 '20: 53.5M Q4 '20: 17.8M Q1 '21: 32M Q2 '21: 79.1M Q3 '21: 114M Q4 '21: 157.2M Q1 '22: 188M Q2 '22: 203.6M Q3 '22: 238.4M Q4 '22: 270.8M Q1 '23: 289.7M Q2 '23: 306.6M Q3 '23: 317.6M Q4 '23: 331.4M Q1 '24: 355.4M Q2 '24: 382.2M Q3 '24: 412.6M Q4 '24: 450.7M Q1 '25: 503.5M Q2 '25: 557.5M Q3 '25: 599.8M Q4 '25: 874.8M Q1 '26: 885.7M Q2 '26: 940.6M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Gross Profit TTM

0 350M 700M 1.1B Q4 '19: 45.1M Q1 '20: 45.4M Q2 '20: 46.9M Q3 '20: 49.7M Q4 '20: 16.3M Q1 '21: 24.6M Q2 '21: 71.4M Q3 '21: 107.2M Q4 '21: 149.9M Q1 '22: 186.5M Q2 '22: 202.1M Q3 '22: 234M Q4 '22: 264.4M Q1 '23: 282.6M Q2 '23: 298.9M Q3 '23: 312.2M Q4 '23: 326.9M Q1 '24: 350.6M Q2 '24: 376.6M Q3 '24: 404.8M Q4 '24: 438.4M Q1 '25: 487.9M Q2 '25: 540.8M Q3 '25: 584.2M Q4 '25: 855.8M Q1 '26: 865.8M Q2 '26: 919.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '10: -34.4M Q1 '11: -43.1M Q2 '11: -47M Q3 '11: -48.9M Q4 '11: -49.6M Q1 '12: -43.1M Q2 '12: -39M Q3 '12: -34.2M Q4 '12: -33.9M Q1 '13: -34.2M Q2 '13: -36.2M Q3 '13: -35.1M Q4 '13: -30.7M Q1 '14: -32.8M Q2 '14: -32.3M Q3 '14: -36.9M Q4 '14: -45.8M Q1 '15: -52.8M Q2 '15: -35.9M Q3 '15: -37.4M Q4 '15: -39.4M Q1 '16: -44.1M Q2 '16: -61.5M Q3 '16: -57.6M Q4 '16: -48.6M Q1 '17: -40.2M Q2 '17: -43.6M Q3 '17: -47.7M Q4 '17: -57.4M Q1 '18: -68.9M Q2 '18: -71.7M Q3 '18: -86.8M Q4 '18: -94.2M Q1 '19: -101.3M Q2 '19: -118M Q3 '19: -124.6M Q4 '19: -99.5M Q1 '20: -111.1M Q2 '20: -114.7M Q3 '20: -122.5M Q4 '20: -174.8M Q1 '21: -185.2M Q2 '21: -176.2M Q3 '21: -177.9M Q4 '21: -177.7M Q1 '22: -176.3M Q2 '22: -181.4M Q3 '22: -154.3M Q4 '22: -148.4M Q1 '23: -126.9M Q2 '23: -112.9M Q3 '23: -107.3M Q4 '23: -103.7M Q1 '24: -89.8M Q2 '24: -60.3M Q3 '24: -40.7M Q4 '24: -2.5M Q1 '25: 33.2M Q2 '25: 54.2M Q3 '25: 76.1M Q4 '25: 341M Q1 '26: -381.8M Q2 '26: -313.2M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q4 '10: -33.9M Q1 '11: -44.3M Q2 '11: -50.4M Q3 '11: -54M Q4 '11: -56.9M Q1 '12: -50M Q2 '12: -46M Q3 '12: -41.2M Q4 '12: -39.1M Q1 '13: -37.5M Q2 '13: -37.4M Q3 '13: -35.7M Q4 '13: -30.1M Q1 '14: -35.7M Q2 '14: -38.2M Q3 '14: -38.9M Q4 '14: -45.2M Q1 '15: -50.2M Q2 '15: -30.7M Q3 '15: -36.6M Q4 '15: -43M Q1 '16: -50.7M Q2 '16: -71.9M Q3 '16: -68.8M Q4 '16: -55.1M Q1 '17: -46.5M Q2 '17: -47.1M Q3 '17: -50.7M Q4 '17: -65.8M Q1 '18: -77.3M Q2 '18: -78.9M Q3 '18: -93.4M Q4 '18: -101.3M Q1 '19: -106.5M Q2 '19: -125.7M Q3 '19: -133.7M Q4 '19: -108.9M Q1 '20: -115.4M Q2 '20: -116.4M Q3 '20: -124.9M Q4 '20: -182.8M Q1 '21: -209.5M Q2 '21: -214.1M Q3 '21: -226.8M Q4 '21: -184.1M Q1 '22: -194M Q2 '22: -209.6M Q3 '22: -193.4M Q4 '22: -247.1M Q1 '23: -226.3M Q2 '23: -242.7M Q3 '23: -236.3M Q4 '23: -226.5M Q1 '24: -208.6M Q2 '24: -145.9M Q3 '24: -123.8M Q4 '24: -88.9M Q1 '25: -53.5M Q2 '25: -35.7M Q3 '25: -8.8M Q4 '25: 263.9M Q1 '26: -458M Q2 '26: -384.7M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 8M 16M 24M Q4 '19: 3.7M Q1 '20: 2.3M Q2 '20: 2.3M Q3 '20: 3.8M Q4 '20: 1.6M Q1 '21: 7.5M Q2 '21: 7.8M Q3 '21: 6.8M Q4 '21: 7.2M Q1 '22: 1.5M Q2 '22: 1.5M Q3 '22: 4.4M Q4 '22: 6.4M Q1 '23: 7.1M Q2 '23: 7.8M Q3 '23: 5.3M Q4 '23: 4.5M Q1 '24: 4.8M Q2 '24: 5.6M Q3 '24: 7.7M Q4 '24: 12.3M Q1 '25: 15.6M Q2 '25: 16.7M Q3 '25: 15.6M Q4 '25: 19.1M Q1 '26: 19.9M Q2 '26: 20.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-300M -150M 0 150M 300M 450M Q2 '11: -32.8M Q3 '11: -34.1M Q4 '11: -32.3M Q1 '12: -30.2M Q2 '12: -33M Q3 '12: -34.4M Q4 '12: -37.4M Q1 '13: -36.3M Q2 '13: -32.9M Q3 '13: -29M Q4 '13: -26.5M Q1 '14: -24.3M Q2 '14: -28.5M Q3 '14: -29.2M Q4 '14: -38.6M Q1 '15: -33.3M Q2 '15: -8.1M Q3 '15: -12.2M Q4 '15: -13.1M Q1 '16: -28.2M Q2 '16: -57.5M Q3 '16: -62.4M Q4 '16: -53.4M Q1 '17: -43.1M Q2 '17: -41.6M Q3 '17: -36.5M Q4 '17: -41.1M Q1 '18: -52.3M Q2 '18: -56.5M Q3 '18: -79.1M Q4 '18: -92.6M Q1 '19: -99.9M Q2 '19: -110.5M Q3 '19: -103.1M Q4 '19: -89.6M Q1 '20: -85.9M Q2 '20: -92.4M Q3 '20: -103M Q4 '20: -135.1M Q1 '21: -172.8M Q2 '21: -167.2M Q3 '21: -152.2M Q4 '21: -142.2M Q1 '22: -158.9M Q2 '22: -161.3M Q3 '22: -170.5M Q4 '22: -161.8M Q1 '23: -131.6M Q2 '23: -122.6M Q3 '23: -110.1M Q4 '23: -95.1M Q1 '24: -101.3M Q2 '24: -83.9M Q3 '24: -55.7M Q4 '24: -52M Q1 '25: -25.9M Q2 '25: 16.8M Q3 '25: 50.2M Q4 '25: 347.4M Q1 '26: 313.1M Q2 '26: 376.1M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-300M -150M 0 150M 300M 450M Q2 '11: -33M Q3 '11: -34.2M Q4 '11: -32.3M Q1 '12: -30.3M Q2 '12: -33.2M Q3 '12: -34.5M Q4 '12: -37.5M Q2 '14: -28.5M Q3 '14: -29.2M Q4 '14: -38.7M Q1 '15: -34M Q2 '15: -9.2M Q3 '15: -13.3M Q4 '15: -18.2M Q1 '16: -36M Q2 '16: -66.8M Q3 '16: -71.7M Q4 '16: -58.7M Q1 '17: -45.1M Q2 '17: -41.8M Q3 '17: -36.7M Q4 '17: -41.5M Q1 '18: -52.6M Q2 '18: -57M Q3 '18: -79.5M Q4 '18: -92.9M Q1 '19: -100.3M Q2 '19: -110.8M Q3 '19: -103.5M Q4 '19: -89.9M Q1 '20: -86.2M Q2 '20: -92.8M Q3 '20: -103.5M Q4 '20: -135.6M Q1 '21: -173.3M Q2 '21: -168.4M Q3 '21: -153.7M Q4 '21: -144.5M Q1 '22: -161.6M Q2 '22: -163.4M Q3 '22: -172.4M Q4 '22: -163.2M Q1 '23: -132.7M Q2 '23: -123.9M Q3 '23: -112.2M Q4 '23: -97.3M Q1 '24: -103.6M Q2 '24: -85.8M Q3 '24: -56.7M Q4 '24: -53.1M Q1 '25: -26.9M Q2 '25: 15.8M Q3 '25: 47.9M Q4 '25: 344.9M Q1 '26: 310.4M Q2 '26: 373.4M Q4 '12 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q2 '14: 63.6M Q3 '14: 71.8M Q1 '15: 72.3M Q2 '15: 76.8M Q3 '15: 73.3M Q1 '16: 73.6M Q2 '16: 73.7M Q3 '16: 73.7M Q1 '17: 75.2M Q2 '17: 80.4M Q3 '17: 83.6M Q1 '18: 98.6M Q2 '18: 98.8M Q3 '18: 105.4M Q1 '19: 110.2M Q2 '19: 110.3M Q3 '19: 110.4M Q1 '20: 154.2M Q2 '20: 161.6K Q3 '20: 176.5K Q1 '21: 177.3M Q2 '21: 178.1M Q3 '21: 179.1M Q1 '22: 184.9M Q2 '22: 185.6M Q3 '22: 186.2M Q1 '23: 188.5M Q2 '23: 189.1M Q3 '23: 189.6M Q1 '24: 206.1M Q2 '24: 206.4M Q3 '24: 206.9M Q1 '25: 215.3M Q2 '25: 219.9M Q3 '25: 219.9M Q1 '26: 242.3M Q2 '26: 265.2M Q3 '14 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-600.00 -400.00 -200.00 0.00 200.00 400.00 600.00 Q4 '10: -0.76 Q1 '11: -0.99 Q2 '11: -1.12 Q3 '11: -1.20 Q4 '11: -1.26 Q1 '12: -1.10 Q2 '12: -0.99 Q3 '12: -0.86 Q4 '12: -0.79 Q1 '13: -0.75 Q2 '13: -0.73 Q3 '13: -0.68 Q4 '13: -0.55 Q1 '14: -0.63 Q2 '14: -0.63 Q3 '14: -0.61 Q4 '14: -0.68 Q1 '15: -0.72 Q2 '15: -0.43 Q3 '15: -0.51 Q4 '15: -0.60 Q1 '16: -0.70 Q2 '16: -0.98 Q3 '16: -0.94 Q4 '16: -0.75 Q1 '17: -0.63 Q2 '17: -0.62 Q3 '17: -0.64 Q4 '17: -0.78 Q1 '18: -0.85 Q2 '18: -0.83 Q3 '18: -0.93 Q4 '18: -0.98 Q1 '19: -1.00 Q2 '19: -1.15 Q3 '19: -1.21 Q4 '19: -0.98 Q1 '20: -0.94 Q2 '20: -240.60 Q3 '20: -500.26 Q4 '20: -500.58 Q1 '21: -500.70 Q2 '21: -260.94 Q3 '21: -1.27 Q4 '21: -1.03 Q1 '22: -1.07 Q2 '22: -1.15 Q3 '22: -1.05 Q4 '22: -1.33 Q1 '23: -1.21 Q2 '23: -1.29 Q3 '23: -1.25 Q4 '23: -1.18 Q1 '24: -1.07 Q2 '24: -0.73 Q3 '24: -0.61 Q4 '24: -0.43 Q1 '25: -0.26 Q2 '25: -0.18 Q3 '25: -0.05 Q4 '25: 1.21 Q1 '26: -1.77 Q2 '26: -1.49 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.